UNSPSC 51182433: Neridronic acid

This classification denotes a bone resorption inhibitor and biphosphonate with the molecular formula C6H17NO7P2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8U27U3RIN4, chemically known as 6-amino-1-hydroxyhexane-1,1-diphosphonate but generally known as neridronic acid, which bears US NIH Compound Identifier 71237. European Medicines Agency schedules Neridronic acid in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09205MIG.

The term NERIDRONIC ACID is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 4, No. 3 1990, List 30). As of Q4 2014, NERIDRONIC ACID remains the US FDA Preferred Term for this commodity. Neridronic acid bears US NLM identifiers UMLS ID C1882065 and NCI Concept Code C66230. SMILES: P(=O)(O)(O)C(P(=O)(O)O)(O)CCCCCN.

UNSPSC 51182433 Neridronic acid is a Commodity code representing branded and generic pharmaceutical products supplied to state and local government facilities through cooperative purchasing agreements. State and local governments procure neridronic acid and related pharmaceutical products as part of broader multi-source drug procurement programs that feed inventory to healthcare facilities, correctional systems, and social-service agencies. The issuing bodies are primarily state procurement offices administering multistate cooperative purchasing consortia—notably the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP)—that aggregate demand across participating states and local jurisdictions to negotiate volume pricing with pharmaceutical manufacturers and establish relationships with authorized wholesale distributors. The code covers both branded and generic drugs across therapeutic categories, with vendors required to meet FDA compliance, Good Manufacturing Practices (cGMP) certification, Drug Supply Chain Security Act (DSCSA) compliance, and supply agreements with authorized wholesalers holding chargeback systems.

The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating states including Oregon. The solicitation requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and evaluates proposals primarily on price competitiveness (75 percent), with secondary weighting on fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. Awarded contracts take effect July 1, 2026, with a two-year initial term and optional extensions. The RFP does not disclose specific award values or budget thresholds.